跳至主要内容
临床试验/EUCTR2022-003041-35-BE
EUCTR2022-003041-35-BE招募中1 期

Impact of the immune system on response to inactivated influenza vaccine (IIV) in allogeneic stem cell recipients - Flu-Allo

CHU de Liège0 个研究点目标入组 100 人开始时间: 2022年9月8日最近更新:
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • - prior allogeneic hematopoietic stem cell transplantation 3 months to 5 years earlier (any donor type except cord blood transplantation); patients > 5 years are also eligible if they are still on systemic immunosuppressive treatment for chronic GVHD.
  • - age> or = 18 years at inclusion.
  • - written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 85
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 15

排除标准

  • - HIV seropositivity
  • - Pregnancy
  • - Active malignant disease
  • - Current grade III-IV acute GVHD
  • - In vitro T-cell depletion of the graft if vaccination within 6 months after transplantation.
  • - Rituximab administration in the 6 months prior to inclusion
  • - IVIg in the 3 months before vaccination.
  • - Prior post-transplant IIV vaccination in the 9 months prior inclusion

研究者

发起方
CHU de Liège

相似试验